title: Weighing the benefits of high-dose simvastatin against the risk of myopathy.
authors.affiliation: Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
authors.forename: Amy
authors.initials: A
authors.lastname: Egan
authors.forename: Eric
authors.initials: E
authors.lastname: Colman
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003402:Creatine Kinase / Q000097:blood; D017277:Drug Approval; D004347:Drug Interactions; D004348:Drug Labeling; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced*; D012306:Risk; D019821:Simvastatin / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000924:Anticholesteremic Agents; D019821:Simvastatin; D003402:Creatine Kinase